Harvard Medical School

Inflammatory Bowel Disease Expert and Harvard Medical School Faculty Dr. Hamed Khalili Joins Vivante Health’s Clinical Advisory Board

Retrieved on: 
Monday, February 26, 2024
Research, American Gastroenterological Association, Inflammatory Bowel Diseases, Education, Colorectal cancer, Physician, Quality of life, Hospital, Epidemiology, Gastrointestinal cancer, Vivante Corporation, American College, Inflammatory bowel disease, Associate, Massachusetts General Hospital, Harvard Medical School, Stanford University Medical Center, State, Nursing

CHICAGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Vivante Health , the employee benefit for GI care, announced the addition of Dr. Hamed Khalili to its Clinical Advisory Board today.

Key Points: 
  • CHICAGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Vivante Health , the employee benefit for GI care, announced the addition of Dr. Hamed Khalili to its Clinical Advisory Board today.
  • Dr. Khalili is a gastroenterologist and Director of Clinical Research at Massachusetts General Hospital, Crohn’s and Colitis Center and an Associate Professor at Harvard Medical School.
  • His research focuses on studying dietary and lifestyle factors and their relationship to the development and progression of inflammatory bowel diseases.
  • “Vivante Health is doing fantastic work to care for people with digestive conditions, particularly in the area of inflammatory bowel disease and other digestive conditions.

BullFrog AI Appoints Globally Renowned Biomedical AI Expert Dr. Thomas W. Chittenden as Chief Scientific Officer

Retrieved on: 
Monday, February 26, 2024
Doctor of Philosophy, Artificial intelligence, Biotechnology, AI, Statistics, Computational biology, Drug development, Drug discovery, Biomarker, Medicine, Disease, Machine learning, Harvard Medical School, HMS Research, Biology, Bullfrog, Medical device

Prior to his role at BioAI Health, Dr. Chittenden was the President, Chief Technology Officer, and Founding Director of the AI/ Scientific Machine Learning (SciML) Research and Development Initiative at HiberCell.

Key Points: 
  • Prior to his role at BioAI Health, Dr. Chittenden was the President, Chief Technology Officer, and Founding Director of the AI/ Scientific Machine Learning (SciML) Research and Development Initiative at HiberCell.
  • At BullFrog AI, Dr. Chittenden will lead the scientific strategy to further develop and implement cutting-edge AI-driven platforms for drug discovery and development.
  • Dr. Chittenden commented, "I am thrilled to join BullFrog AI and to contribute to the Company's innovative approach to drug development.
  • Dr. Chittenden's appointment as Chief Scientific Officer of BullFrog AI, effective February 26, 2024, marks a significant milestone for the Company as it continues to pioneer a new era of AI technology-enabled drug development.

Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs

Retrieved on: 
Thursday, February 22, 2024
ACT, Massachusetts General Hospital, Mass, Master of Science, NINDS, Bangladesh Technical Education Board, Neuromuscular disease, ALS, CNM, Doctor of Philosophy, NIH, FDA, Record, Hospital, Risk, Natural history, EAPS, Multiple sclerosis, Safety, Data, Patient, Survival, Disease, Harvard Medical School, Columbia University, EAP, Mortality, DSM-IV codes, Pharmaceutical industry

CNM-Au8 30 mg treatment was well-tolerated, without a single serious adverse event attributed to CNM-Au8, and no significant safety findings reported.

Key Points: 
  • CNM-Au8 30 mg treatment was well-tolerated, without a single serious adverse event attributed to CNM-Au8, and no significant safety findings reported.
  • A pooled survival analysis of EAP participants treated with CNM-Au8 30 mg was compared to two independent datasets derived from PRO-ACT and the ALS/MND Natural History Consortium.
  • The EAP dataset was comprised of 256 participants with ALS of which 220 EAP participants had all baseline values available for matching.
  • The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and Clene supported the first EAP (EAP01) launched in 2019.

RS BioTherapeutics Creates Therapeutic Expert Council to Provide Guidance on Development of First-in-Class Agent Focused on Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

Retrieved on: 
Wednesday, February 21, 2024
TEC, IPF, University, Idiopathic disease, Division, Assistant, Critical care, Idiopathic pulmonary fibrosis, Chronic obstructive pulmonary disease, Clinical research, Outline of health sciences, Consultant, Respiratory Medicine, Death, SUNY, Observation, Harvard Medical School, COPD, Pharmaceutical industry

CUMBERLAND, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce the formation of its Therapeutic Expert Council (TEC).

Key Points: 
  • CUMBERLAND, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce the formation of its Therapeutic Expert Council (TEC).
  • The TEC will help guide the development of RS BioTherapeutics’ first-in-class, steroid-free agent, RSBT-001, in development for Chronic Obstructive Pulmonary Disease (COPD), the third leading cause of death in the world; and Idiopathic Pulmonary Fibrosis (IPF), a rare disease with no cure that claims 40,000 lives each year in the U.S.
  • All have exceptional credentials and are uniquely qualified to help support the development of our first investigational compound, RSBT-001.
  • I’m excited to collaborate with them and look forward to engaging their diverse perspectives spanning the fields of COPD, IPF, and other diseases characterized by pulmonary inflammation.”

Fujifilm Celebrates Recent Recipients of Fujifilm Fellowships at Harvard Medical School

Retrieved on: 
Tuesday, February 20, 2024
Lilium, Therapy, Research, Doctor of Philosophy, Drug resistance, Chemical biology, G protein-coupled receptor, Biology, Obesity, Pain, MIT, Harvard University, Drug discovery, Eurosport 1, Health, Fujifilm, Faculty (division), Disease, Massachusetts General Hospital, Harvard Medical School, Infection, Publication, Faculty, Fujifilm Diosynth Biotechnologies, Management

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced the nine most recent Fujifilm Fellows at Harvard Medical School.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced the nine most recent Fujifilm Fellows at Harvard Medical School.
  • These PhD students from around the world are part of the Harvard Medical School Therapeutics Graduate Program working to advance therapeutics discovery, development, and applications to improve the treatment of disease.
  • Launched with six fellows in 2019, the Fujifilm Fellowship has now grown to reach 34 recipients to date, including six alumni.
  • “Fujifilm is proud to support Harvard Medical School as it helps to shape our world’s future scientists.

Neuroelectrics Announces Results of Telemedicine Pilot Depression Study with Starstim tDCS Therapy

Retrieved on: 
Thursday, March 7, 2024
Science, Biotechnology, Telemedicine, Virtual Medicine, Research, Health, Mental Health, Medical Devices, Clinical Trials, Electrode, Depressive, Multimedia, Preprint, Satisfaction, Grammatical mood, Quick, Deep brain stimulation, Safety, Quality of life, Patient, DSM-IV codes, Harvard Medical School, MDD, Brain, Depression, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240307614300/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240307614300/en/
    The preprint, titled “Multichannel tDCS with Advanced Targeting for Major Depressive Disorder: A Tele-Supervised At-Home Pilot Study,” highlights results from a multicenter, open-label feasibility telemedicine pilot study that studied the efficacy, safety, and feasibility of home-based tDCS using Starstim to target the L-DLPFC.
  • The study was conducted across multiple centers and involved 35 participants diagnosed with medication-resistant MDD to evaluate tDCS administered at home using Neuroelectrics’ Starstim device.
  • Results from this study highlight the safety and feasibility of at-home tDCS, with nearly 90% of participants completing the treatment without experiencing any adverse effects.
  • “We’re excited to announce the results of our telemedicine pilot study, showcasing the transformative potential of at-home tDCS therapy with our Starstim device in managing MDD,” said Ana Maiques, CEO & Co-Founder, Neuroelectrics.

Elicit Plant Announces the Appointment of Slavica Djonovic, Ph.D, as Chief Scientific Officer (CSO)

Retrieved on: 
Thursday, March 7, 2024
Biotechnology, Other Health, Health, Other Natural Resources, Agriculture, Other Science, Natural Resources, Research, Environment, Science, Sustainability, Senior, Multimedia, Synthetic biology, Farmer, Growth, Hospital, Agtech, Colorado State University, Climate change, Patent, Intellectual property, Knowledge, Texas A&M University, Slavica, Massachusetts General Hospital, Harvard Medical School, CSO

Elicit Plant, a pioneering and rapidly expanding agri-biotech company, announces the appointment of the renowned scientist and a leader in the ag-tech industry, Slavica Djonovic, Ph.D. as Chief Scientific Officer (CSO).

Key Points: 
  • Elicit Plant, a pioneering and rapidly expanding agri-biotech company, announces the appointment of the renowned scientist and a leader in the ag-tech industry, Slavica Djonovic, Ph.D. as Chief Scientific Officer (CSO).
  • Elicit Plant's proprietary technology, EliTerra®, the consistent performance of its products internationally, and its team driven by a clear mission, are impressive," states Slavica Djonovic, CSO of Elicit Plant.
  • "In her new role as Chief Scientific Officer, Slavica will be tasked with amplifying Elicit Plant's scientific influence and accelerating the development of our EliTerra® Technological platform.
  • We are convinced that under her scientific leadership, Elicit Plant will reach a new milestone in developing innovative solutions for agriculture," concludes Jean-François Déchant, CEO of Elicit Plant.

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

Retrieved on: 
Wednesday, March 6, 2024
Pharmaceutical, AIDS, Health, Clinical Trials, Infection, Bangladesh Technical Education Board, SHIV, AD8, Research, Virology, BCG, NIAID, FDA, Safety, Animal, Hook effect, NMIBC, Rockefeller University, ART, Viremia, Patient, NK, Harvard Medical School, HIV, HIV/AIDS, Immune system, Vaccine

Treatment with N-803 and bNAbs led to immune activation and transient viremia, but only limited reductions in the SHIV reservoir.

Key Points: 
  • Treatment with N-803 and bNAbs led to immune activation and transient viremia, but only limited reductions in the SHIV reservoir.
  • Upon ART discontinuation, all animals experienced viral rebound, followed by long-term virus control for up to 10 months in approximately 70% of those treated with N-803 and bNAbs.
  • “When combined with broadly neutralizing antibodies, N-803 has the potential to provide viral control without significant reduction in the viral reservoir, which further suggests that the complete eradication of this reservoir may not be required to induce sustained remission after discontinuing antiretroviral therapy."
  • Safety and efficacy have not been established by any Health Authority or Agency, including the FDA.

Ankyra Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Dose Escalation Cohort Evaluating ANK-101, an Anchored Immune Medicine, for Solid Tumors

Retrieved on: 
Tuesday, March 5, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Mass, Toxicity, Aluminium, Neoplasm, Immunotherapy, MBA, Safety, Therapy, Tumor microenvironment, Patient, Medicine, Harvard Medical School, RDE, Trial of the century, Cancer, Pharmaceutical industry

Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced the first patient dosed in the dose escalation cohort in a Phase 1 clinical study evaluating ANK-101, a tumor-directed, anchored immune medicine for solid tumors.

Key Points: 
  • Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced the first patient dosed in the dose escalation cohort in a Phase 1 clinical study evaluating ANK-101, a tumor-directed, anchored immune medicine for solid tumors.
  • ANK-101 is currently under investigation in patients with advanced solid tumors who have failed standard of care treatments.
  • In multiple preclinical models, ANK-101 demonstrated increased immune cell infiltration into tumors without systemic toxicity.
  • “These data will provide a roadmap for advancing ANK-101 through clinical development and for identifying appropriate clinical indications for future trials,” said Joe Elassal, M.D., MBA, Chief Medical Officer of Ankyra Therapeutics.

Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers

Retrieved on: 
Tuesday, March 5, 2024
Technology, Diabetes, Health, Apps, Applications, Pharmaceutical, Mental Health, Telemedicine, Virtual Medicine, Medical Devices, Software, General Health, Health Technology, Fitness & Nutrition, Clinical Trials, Cardiology, T2D, Nutrition, Randomized controlled trial, Education, Conditional sentence, Obesity, FDA, Food, White House conference, CHC, Federally Qualified Health Center, A1C, Conference, ACLM, Better, Therapy, Type 2 diabetes, American College, Food and Drug Administration, Patient, NTI, RCT, Medicine, Society, Harvard Medical School, Community health center, Prescription, FQHC, Partnership, Pharmaceutical industry

Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx , available to support underserved patients through 1,400 Federally Qualified Health Center (FQHC) organizations.

Key Points: 
  • Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx , available to support underserved patients through 1,400 Federally Qualified Health Center (FQHC) organizations.
  • This underscores the urgent need for evidence-based interventions to ensure equitable access to high-quality care for all.
  • The Lifestyle Medicine National Training Initiative (NTI) is an extension of ACLM’s $24.1 million commitment to the 2022 White House Conference on Hunger, Health, and Nutrition .
  • Better Therapeutics and ACLM are seeking additional partners and funding to support the implementation and maximize the initiative’s impact.